Glucagon News and Research

RSS

Lilly acquires worldwide rights to intranasal glucagon from Locemia

Eli Lilly and Company and Locemia Solutions today announced Lilly has acquired worldwide rights to Locemia's intranasal glucagon, a potential treatment for severe hypoglycemia in people with diabetes treated with insulin. Intranasal glucagon, which is currently in Phase III clinical trial testing, could be the first needle-free rescue treatment for severe hypoglycemia.

11 Oct 2015

Type-2 diabetes medication can affect the brain's reward system, reduce intake of food

Many studies have focused on how much we eat when we are hungry, but sometimes we eat just to feel better. A new dissertation at Sahlgrenska Academy shows that medication used for type-2 diabetes wich mimics the gut-brain hormone glucagon-like peptide-1, can affect the brain's reward system and reduce the intake of food.

29 Sep 2015

New study highlights gap in scientific knowledge about some diabetes drugs

A gap in scientific knowledge about a family of drugs that are used to treat Type 2 diabetes has been highlighted in a new study.

21 Sep 2015

AstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting of EASD

AstraZeneca today announced new analyses of exenatide once weekly (ExQW) demonstrating a favorable gastrointestinal (GI) tolerability profile, including less frequent upper and lower GI adverse events (AE), compared to shorter-acting glucagon-like peptide-1 receptor agonists (GLP-1RA), exenatide twice daily (ExBID) and liraglutide once daily (LiraQD).

16 Sep 2015

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial.

31 Aug 2015

GLP-2 therapy may help fight neonatal parenteral nutrition-associated liver disease

A new study finds that exogenous glucagon-like peptide 2 (GLP-2) treatment may help fight neonatal parenteral nutrition-associated liver disease (PNALD).

28 Jul 2015

Lilly Diabetes releases Android version of Glucagon Mobile App to support diabetes caregivers

Lilly Diabetes has released an Android version of its mobile application designed for caregivers and healthcare providers who support people with diabetes. Through an injection tutorial and emergency instructions, the App can help people practice the injection steps ahead of time, which may help them feel better prepared to assist.

15 Jul 2015

Understanding crosstalk between cells in the pancreas can help treat diabetes

Sometimes, listening in on a conversation can tell you a lot. For Mark Huising, an assistant professor in the Department of Neurobiology, Physiology and Behavior at the UC Davis College of Biological Sciences, that crosstalk is between the cells that control your body's response to sugar, and understanding the conversation can help us understand, and perhaps ultimately treat, diabetes.

16 Jun 2015

Paediatric outpatient study compares effectiveness of three alternative treatments for type 1 diabetes

A Montréal research team, co-supervised by Dr. Rémi Rabasa-Lhoret from the IRCM and Dr. Laurent Legault from the Montreal Children's Hospital, undertook the first paediatric outpatient study to compare three alternative treatments for type 1 diabetes.

11 Jun 2015

Study shows how GLP-1 receptor agonists modify the brain's response to food

Gut hormone-based medications used to treat diabetes, such as GLP-1 receptor agonists, have also been shown to reduce body weight. Researchers have been working to understand how. This study, presented today at the American Diabetes Association's 75th Scientific Sessions, sheds light on how GLP-1 receptor agonists alter the brain's response to food, possibly reducing cravings and increasing satisfaction while eating.

9 Jun 2015

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating the range of treatment options represented in Lilly's diabetes portfolio will be presented in 79 abstracts on June 5-9, at the 75th American Diabetes Association (ADA)® Scientific Sessions in Boston.

29 May 2015

Diabetes drug liraglutide could prove to be a new treatment option for NASH

A drug approved to treat type 2 diabetes could prove to be a powerful new treatment option for non-alcoholic steatohepatitis (NASH), according to research presented today at The International Liver Congress 2015. Results from a randomised controlled trial showed liraglutide met the primary endpoint of histological clearance of NASH, and a reduction in the progression of fibrosis.

23 Apr 2015

New class of drugs targeting blood glucose level could benefit individuals with type 2 diabetes

Individuals with type 2 diabetes, who are resistant to insulin, have an excess blood glucose level, which they are now trying to reduce using a new class of diabetes drugs known as the gliflozins.

22 Apr 2015

UC Davis assistant professor wins Hartwell Foundation award to explore treatment for juvenile diabetes

UC Davis Assistant Professor Mark Huising is a recipient of The Hartwell Foundation 2014 Individual Biomedical Research Award to support his early-stage research toward a cure for juvenile diabetes. Diabetes affects 10 percent of the entire United States population, including approximately a million children. Remarkably, 40 children every day receive the diagnosis of diabetes.

22 Apr 2015

OSU engineers use 'additive manufacturing' to create glucose sensor for patients with diabetes

Engineers at Oregon State University have used "additive manufacturing" to create an improved type of glucose sensor for patients with Type 1diabetes, part of a system that should work better, cost less and be more comfortable for the patient.

18 Mar 2015

Tel Aviv University study proposes new way to suppress glucose surges

Our modern epidemic of obesity has led to an alarming rise in the incidence of diabetes. More than 382 million people on the planet suffer from diabetes, predominantly type-2 diabetes. For these people, blood sugar surges -- glucose spikes after meals -- can be life threatening, leading to cardiovascular complications.

17 Mar 2015

DPP-4 inhibitors effective against low blood sugar levels

DPP-4 inhibitors are a group of drugs used to treat type 2 diabetes that lower high blood sugar levels by stimulating insulin production in the body. Researchers at Lund University in Sweden have now discovered that DPP-4 inhibitors are also effective against low blood sugar levels.

23 Feb 2015

University of Alberta researcher named winner of A.S.P.E.N.'s 2015 Harry M. Vars Award

David Lim, MD, CM, of the University of Alberta has been named the winner of the 2015 Harry M. Vars Award by the American Society for Parenteral and Enteral Nutrition. The award is for his research on parenteral nutrition associated liver disease (PNALD) in infants, which was presented at A.S.P.E.N.'s Clinical Nutrition Week conference in Long Beach, California, February 14 to 17.

19 Feb 2015

University of Alberta's David Lim named recipient of Research Trainee Award by A.S.P.E.N.

David Lim, MD, CM, of the University of Alberta has been named a Research Trainee Award recipient by the American Society for Parenteral and Enteral Nutrition. The award is for his research on parenteral nutrition associated liver disease (PNALD) in infants that he will present at A.S.P.E.N.'s Clinical Nutrition Week conference in Long Beach, California, February 14 to 17.

6 Feb 2015

Postprandial glucagon linked to glycaemic control in Type 1 diabetes

Research shows that postprandial glucagon levels increase over time in children with newly diagnosed Type 1 diabetes, and are associated with worsening glycaemic control, suggesting an adjunctive treatment approach.

30 Jan 2015